Welcome to LookChem.com Sign In|Join Free

CAS

  • or

630390-72-6

Post Buying Request

630390-72-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

630390-72-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 630390-72-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,3,0,3,9 and 0 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 630390-72:
(8*6)+(7*3)+(6*0)+(5*3)+(4*9)+(3*0)+(2*7)+(1*2)=136
136 % 10 = 6
So 630390-72-6 is a valid CAS Registry Number.

630390-72-6Downstream Products

630390-72-6Relevant articles and documents

SERTRALINE COMPOSITIONS

-

Page 29; 32, (2008/06/13)

An acid salt of sertraline, wherein the acid is citric acid, fumaric acid, malic acid, maleic acid, malonic acid, phosphoric acid, succinic acid, sulfuric acid, L-tartaric acid, HBr, acetic acid, benzoic acid, benzenesulfonic acid, ethanesulfonic acid, la

Salt Selection and Simultaneous Polymorphism Assessment via High-Throughput Crystallization: The Case of Sertraline

Remenar, Julius F.,MacPhee, J. Michael,Larson, Bridget K.,Tyagi, Viraj A.,Ho, Jason H.,McIlroy, David A.,Hickey, Magali B.,Shaw, Paul B.,Almarsson, Oern

, p. 990 - 996 (2013/09/05)

High-throughput (HT) crystallization experiments were conducted with sertraline free base in the presence of mono-, di-and triacidic salt formers. Over 3600 crystallization trials were conducted, leading to the identification and characterization of 18 crystalline salt forms. Due to the large number of crystallization conditions for a given salt type, it was possible to gauge the propensity of a given salt form to exhibit polymorphism. Four salt forms were found to exist (in this limited screen) as monomorphic materials. Unlike the HCl salt in the marketed drug product, the HBr salt appears resistant to polymorphism, crystallizing as a single form from over 140 discrete trials. This observation underscores the lack of predictability of polymorphic behavior of pharmaceuticals even when seemingly minor changes to the composition are made. The experiments highlight the importance of coupling salt selection studies with simultaneous polymorph screening to gain a more comprehensive understanding of solid form diversity as part of the form selection process for pharmaceutical development.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 630390-72-6